Versalya Pharma

What Versalya Pharma does

Versalya Pharma S.L. is a Spanish pharmaceutical affiliate, wholly owned by the privately held Italian Italfarmaco Group (founded 1938, €650M turnover, 2,100+ employees, presence in 40 countries). Versalya was established in Alcobendas, Madrid in 2012 with the explicit mandate of developing the Italfarmaco Group's business in Africa and the Middle East, and supplements this role with a regional headquarters in Dubai Media City (Versalya Pharma FZ-LLC) for the Middle East cluster.

The company sells a 12-SKU portfolio of women's and children's health products, organized into four categories: pharmaceutical products (8 SKUs including ACFOL, APIRETIL, BLISSEL, FERPLEX, NATECAL D, NATEMILLE, PROGEVA, YODOCEFOL), food supplements (NATALBEN PLUS, OVUSITOL), cosmetics (ZELESSE), medical devices (AINARA), and functional foods (REHYDRAMIN). The portfolio addresses maternal-health and pediatric therapeutic areas, including iron-deficiency anemia, progesterone deficiency, vitamin D/calcium deficiency, iodine and folate deficiency, vaginal atrophy, and oral rehydration. All products are manufactured by the Italfarmaco Group at GMP- and EMA-certified facilities in Milan (10,000 m² injectable plant: 60M ampoules, 80M pre-filled syringes, 10M blisters annually) and Madrid (6,000 m² liquid oral plant: 50M ampoules, 60M bottles, 150M sachets annually), then registered country-by-country in target markets. There is no proprietary technology platform; the differentiated intellectual property is the group's iron proteinsuccinylate formulation behind FERPLEX, which is reported as the market leader in several European countries.

Versalya's go-to-market is a hybrid enterprise field-sales and event-driven model: products are sold via registered distributors and wholesalers across 20+ countries (Pakistan, UAE, Yemen, Saudi Arabia, Lebanon, Iraq, Algeria, Tunisia, Libya, Senegal, Mali, Ivory Coast, Togo, Benin, Burkina Faso, Cameroon, Gabon, Congo, Mauritania, Chad, Central African Republic, Niger, Angola, South Africa, Nigeria), and the company simultaneously engages gynecologists, obstetricians, and pediatricians through scientific congresses, symposia (Progeva launch in Algiers, 2017; SOMAGO congress in Bamako, 2016), and an Annual Scientific Meeting in gynecology held in Madrid. Primary end customers are women from pre-conception through breastfeeding and children aged 0-7, reached through prescribing healthcare professionals. Revenue mechanics are one-time product sales (no subscription, licensing, or SaaS component), with no public pricing disclosure and no direct revenue figure released; headcount is 501-1,000 employees per firmographic data.

Name

Versalya Pharma

Legal name

Versalya Pharma S.L.

Website

https://versalya-pharma.com

Company type

Private

Founded year

2012

Operating status

Operating

Headcount range

501–1,000 employees

Short description

Versalya Pharma is a Spanish pharmaceutical affiliate of the Italfarmaco Group that registers and distributes European-manufactured women's and children's health products (pharmaceuticals, supplements, medical devices) across 20+ African and Middle Eastern markets via distributor networks and HCP engagement at medical congresses.

Ownership category

akta.pro rank

Product category

Women's and Children's Health Pharmaceuticals

NAICS

Pharmaceutical Preparation Manufacturing (325412), Drugs and Druggists' Sundries Merchant Wholesalers (424210)

SIC

Pharmaceutical Preparations (2834), Perfumes, Cosmetics & Other Toilet Preparations (2844)

akta.pro primary industry

Endocrinology & Reproductive Health Pharmaceuticals (incl. Women’s Health) (HLAIAAAJ)

akta.pro secondary industries

Women’s Health Supplements (Prenatal, Menopause, Hormonal) (CRADAGAK), Specialty Condition Supplements (Sleep, Stress, Heart, Joint, Gut, Immunity) (CRADAGAE)

Keywords

• Women's health pharmaceuticals
• Gynecology medications
• Pediatric healthcare products
• Prenatal supplements
• Iron deficiency treatment

Headquarters

HQ city

Alcobendas

HQ country

Spain

HQ region

Europe

Offices5 records

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Supply Chain, Personnel, Marketing or Sales, Operations, Technology or R&D

Revenue model

1. Pharmaceutical Products: Prescription and OTC pharmaceutical products including gynecological and pediatric medications sold to healthcare providers across Africa and Middle East markets.
2. Food Supplements: Dietary supplements for women's health including prenatal vitamins, inositol combinations, and nutritional products sold alongside pharmaceutical offerings.
3. Medical Devices: Medical devices including intimate care products and oral rehydration solutions for women and children.
4. Cosmetics: Cosmetic products including intimate hygiene solutions for women.
5. Functional Foods: Functional food products including oral rehydration solutions for children and adults.

Go-to-market motion2 records

Distribution channels1 record

Marketing channels4 records

Core offering

Versalya Pharma manufactures and distributes a portfolio of European-made pharmaceutical products, food supplements, cosmetics, medical devices, and functional foods focused on women's and children's health. The company sells its products through regional distributors to healthcare professionals across 20+ countries in Africa and the Middle East. Its product range covers gynaecology (progesterone, vaginal atrophy, fertility, prenatal nutrition) and paediatrics (paracetamol, oral rehydration).

Product overview

Versalya Pharma offers a portfolio of pharmaceutical products, food supplements, cosmetics, medical devices, and functional foods focused on women's and children's health across gynaecology and paediatrics therapeutic areas. The product portfolio includes 8 pharmaceutical products (ACFOL®, APIRETIL®, BLISSEL®, FERPLEX®, NATECAL D®, NATEMILLE®, PROGEVA®, YODOCEFOL®) for treating conditions like folic acid deficiency, pain/fever, vaginal atrophy, iron deficiency, calcium/vitamin D deficiencies, and progesterone disorders. Food supplements include NATALBEN PLUS® and OVUSITOL® for prenatal and pregnancy nutrition. The portfolio also includes ZELESSE® cosmetics for intimate hygiene, AINARA® medical device for vaginal comfort, and REHYDRAMIN® functional food for oral rehydration. All products are manufactured in Europe to international quality standards (GMP and EMA) by the Italfarmaco Group.

Differentiator

Problem solved

Functional benefit

Products and services

• ACFOL® Folic acid 5mg tablets for prevention and treatment of folic acid deficiency, megaloblastic anemias, and prevention of neural tube defects in offspring. Pharmaceutical product for healthcare professionals and patients.
• APIRETIL® Paracetamol 100mg/ml oral solution in 60ml bottles with oral syringes for symptomatic treatment of light to moderate pain and fever reduction in children. Pharmaceutical pediatric product.
• BLISSEL® Vaginal gel containing estriol 50µg/g in 10g pack with applicators for local treatment of vaginal dryness due to lack of oestrogens after menopause. Pharmaceutical gynaecological product.
• FERPLEX® Iron proteinsuccinylate 800mg oral solution (equivalent to 40mg Fe3+) per 15ml for treatment of latent or overt iron deficiency anemia in children and adults. Pharmaceutical iron supplement product.
• NATECAL D® Calcium carbonate 1500mg with cholecalciferol (Vitamin D3) 400 I.U. in 60 orodispersible tablets for treatment of calcium and Vitamin D deficiencies. Pharmaceutical product.
• NATEMILLE® 1000 IU Vitamin D with 600mg Calcium in 30 orodispersible tablets for treatment of vitamin D deficiencies in patients needing additional calcium. Pharmaceutical product.
• PROGEVA® Natural micronized progesterone capsules available in 100mg (box of 30) and 200mg (box of 15) for disorders related to progesterone deficit, luteal phase supplementation during IVF, and prevention of repeated abortions. Pharmaceutical gynaecological product.
• YODOCEFOL® Tablets containing folic acid 400µg and vitamin B12 2µg for prevention of iodine deficiency disorders, and folic acid and vitamin B12 deficiency, used one month before conception and during first trimester of pregnancy. Pharmaceutical product.
• NATALBEN PLUS® Dietary supplement covering nutritional requirements of pregnancy and breastfeeding, containing folic acid, vitamins B1-B3-B5-B6-B12, biotin, iodine, iron, zinc, vitamin C, vitamin D, selenium, and Omega-3 (DHA). Available in boxes of 10 or 30 capsules.
• OVUSITOL® Food supplement with Myo-Inositol 2g and folic acid 200µg per 30 sachets for inositol and folic acid integration in case of dietary deficiency or increased need.
• ZELESSE® Antipruritic cleansing solution with burdock, aloe vera, and chamomile for daily intimate hygiene. Soap, colouring, and paraben free. Used for vulvovaginitis in women and girls, or for sensitive or irritated skin.
• AINARA® Water-based mucoadhesive intimate gel for relief of vulvovaginal atrophy symptoms, vaginal dryness and discomfort during pregnancy, postpartum, menopause, or associated with oral contraceptives.
• REHYDRAMIN® Jellified low-osmolality oral rehydration solution with electrolytes (sodium, chloride, potassium, citrate) and glucose, available in Orange, Lemon, and Strawberry flavors as 8 freezable sticks of 62.5ml. Functional food for dehydration treatment in children and adults.

Quantifiable outcome

• 38.2% of pregnant women worldwide suffer from anemia (WHO data) - FERPLEX addresses iron deficiency with reduced side effects
• +1 more outcomes

Named customers3 records

Segments3 records

Ideal customer profiles2 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Scale indicators5 records

Recent moves6 records

Expansion highlights5 records

Direct peers

• Cipla: Indian multinational pharmaceutical company with a deep presence across Africa (third-largest pharma by volume in South Africa) and a strong respiratory, women's health, and pediatric portfolio. Comparable business model of affordable branded generics distributed via local partners across the same emerging-market geographies.
• Organon: Global women's-health-focused pharmaceutical company (spun off from Merck in 2021) with established franchises in fertility, contraception, and menopause across more than 140 markets. Direct therapeutic-area peer with overlapping portfolio in progesterone, hormone therapy, and women's reproductive health.
• Aspen Pharmacare: South African-headquartered pharmaceutical company with the largest commercial footprint in African markets, including branded generics, women's health, and pediatric portfolios. Direct peer because it serves the same African HCPs and patients via local distribution, with overlapping therapeutic focus.
• Emcure Pharmaceuticals: Indian pharmaceutical company with significant women's health and emerging-markets exposure, manufacturing generics and biosimilars distributed across Africa, Asia, and Latin America. Comparable business model of affordable branded pharmaceuticals in women's health distributed via local partners.
• Theramex: Global specialty pharmaceutical company exclusively focused on women's health (contraception, fertility, menopause, osteoporosis). Direct peer because of identical therapeutic mandate, prescriber channel (OB/GYNs), and product overlap (e.g., progesterone, calcium/vit D for postmenopausal women).
• Gedeon Richter: Hungary-headquartered pharmaceutical company with a long-standing women's health franchise (gynaecology, fertility, contraception) and active CEE, CIS, and Western European markets. Comparable specialty-pharma profile, branded women's health positioning, and OB/GYN-focused sales model.
• Exeltis: Also a women's-health-focused pharmaceutical affiliate of the Italfarmaco Group, operating across Europe and Latin America. Closest structural peer because both share the same parent, the same women's health/therapeutic focus, and a similar affiliate-distributor GTM model in fragmented regional markets.

Broad incumbents

• Bayer (Women's Health / Pharmaceuticals): Global pharmaceutical conglomerate with a legacy women's health franchise (oral contraceptives, IUDs, menopause therapies) and significant Africa/MEA operations. Comparable as an established multinational women's health incumbent, but broader portfolio and global rather than regional focus.
• Sanofi: Global pharmaceutical company with one of the broadest African commercial footprints among multinational pharma, plus established women's health, pediatric, and consumer health portfolios. Comparable as a broad incumbent serving the same HCP channel across the same emerging markets, though women's health is only one of many franchises.

Emerging players

• Strides Pharma Science: Indian pharmaceutical company with a manufacturing-led model supplying affordable generic and specialty products, including women's health and pediatric formulations, to African, Asian, and other emerging markets via local distributors. Comparable as an emerging-market specialty generics peer pursuing similar customer segments and channels.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks5 records

Key highlights6 records

Customer concentration

• LinkedInlinkedin.com/company/versalya-pharma

Revenue estimate

Valuation estimate

Number of profiles

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Versalya Pharma